Drugmaker Wockhardt Ltd said on Wednesday it has received a tentative approval from the US Food & Drug Administration for marketing various doses of anti-bacterial Levofloxacin.                                            Levofloxacin is the generic name for the brand Levaquin, marketed in the US by Ortho Mcneil.                                            Wockhardt will launch the product immediately upon expiration of the patent on June 20, 2011, it said in a press release to the National Stock Exchange.

COMMERCIAL BREAK
SCROLL TO CONTINUE READING